Value Partners Investments Inc. Buys 3,247 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Value Partners Investments Inc. increased its stake in Thermo Fisher Scientific Inc. by 46.2%, acquiring an additional 3,247 shares during the second quarter, bringing its total holdings to 10,280 shares valued at approximately $4.16 million.
• Thermo Fisher Scientific reported $5.36 earnings per share for the last quarter, surpassing analysts' expectations of $5.22, and had a revenue of $10.86 billion, beating the consensus estimate.
• The company declared a quarterly dividend of $0.43 per share, which will be paid on October 15th, and has an annualized dividend yield of 0.4%.

Value Partners Investments Inc. grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 46.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,280 shares of the medical research company's stock after purchasing an additional 3,247 shares during the quarter. Value Partners Investments Inc.'s holdings in Thermo Fisher Scientific were worth $4,161,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of TMO. Revolve Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after purchasing an additional 20 shares during the period. Monograph Wealth Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock valued at $4,507,000 after buying an additional 23 shares in the last quarter. Intergy Private Wealth LLC increased its stake in shares of Thermo Fisher Scientific by 5.8% in the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock worth $208,000 after acquiring an additional 23 shares in the last quarter. Root Financial Partners LLC lifted its position in Thermo Fisher Scientific by 5.0% during the 1st quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock valued at $252,000 after acquiring an additional 24 shares during the period. Finally, Rossmore Private Capital boosted its stake in Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company's stock worth $2,315,000 after acquiring an additional 24 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded up $6.24 during trading hours on Tuesday, hitting $480.70. The stock had a trading volume of 1,799,780 shares, compared to its average volume of 1,482,249. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77. The stock has a fifty day moving average price of $469.07 and a 200 day moving average price of $450.41. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market capitalization of $181.52 billion, a PE ratio of 27.80, a PEG ratio of 2.53 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the firm earned $5.37 EPS. The business's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is 9.95%.

Insiders Place Their Bets

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 over the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

TMO has been the subject of several recent research reports. UBS Group lifted their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. William Blair started coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating for the company. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Finally, Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a report on Friday, July 11th. Seventeen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $592.24.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.